Back to top
more

Exact Sciences (EXAS)

(Delayed Data from NSDQ)

$69.80 USD

69.80
2,470,028

+0.87 (1.26%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $69.80 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Exact Sciences (EXAS) Outpaces Stock Market Gains: What You Should Know

Exact Sciences (EXAS) closed the most recent trading day at $94.56, moving +1.37% from the previous trading session.

Exact Sciences (EXAS) Dips More Than Broader Markets: What You Should Know

Exact Sciences (EXAS) closed the most recent trading day at $87.93, moving -1.83% from the previous trading session.

Exact Sciences, GameStop, Intel, Intuitive Surgical and Skyworks highlighted as Zacks Bull and Bear of the Day

Exact Sciences, GameStop, Intel, Intuitive Surgical and Skyworks highlighted as Zacks Bull and Bear of the Day

What's in Store for IDEXX Laboratories' (IDXX) Q4 Earnings?

IDEXX's (IDXX) is likely to report strong earnings for Q4, courtesy of a global surge in CAG Diagnostic revenues.

Can Critical Care Aid Edwards Lifesciences (EW) Q4 Earnings?

Robust customer adoption of the HemoSphere all-in-one monitoring platform is likely to have driven Edwards Lifesciences' (EW) Q4 revenues.

Kevin Cook headshot

Bull of the Day: Exact Sciences (EXAS)

Massive growth in Cologuard may be slowing but cancer detection is their game and multiple targets are in sight

Will New Buyouts Aid Quest Diagnostics (DGX) Q4 Earnings?

Quest Diagnostics' (DGX) acquisition of Clinical Laboratory Services of Boston Clinical Laboratories is expected to have been accretive to its Q4 earnings.

Will Segmental Growth Aid Hologic (HOLX) in Q1 Earnings?

Strength in segmental businesses is likely to have aided Hologic's (HOLX) performance in first-quarter fiscal 2020.

What's in Store for Align Technology's (ALGN) Q4 Earnings?

Align Technology (ALGN) is expected to have gained from continued adoption of Invisalign system in Q4.

Can Abbott (ABT) Q4 Earnings Ride on Growth in All Lines?

Abbott's (ABT) imminent quarterly results are expected to reflect a solid performance by the Established Pharmaceuticals Division (EPD) business alike the last reported quarter.

Exact Sciences (EXAS) Provides Q4 Expectations, Stock Falls

Exact Sciences (EXAS) revenue growth will likely beat expectations for both the fourth quarter and 2019.

Novavax Rises on Fast Track Designation to Influenza Vaccine

The FDA bestows a Fast Track Designation on Novavax's (NVAX) influenza vaccine candidate NanoFlu for adults aged 65 years and older. Shares rally.

Perrigo (PRGO) Rises on Stellar Q419 Preliminary Results

Perrigo (PRGO) announces better-than-expected preliminary results for fourth-quarter 2019 as well as the full year. Shares gain.

Can Focus on High-Growth Area Up OrganiGram (OGI) Q1 Earnings?

OrganiGram (OGI) is expected to have benefited from its firm focus on building brand equity and ongoing product innovation in the fiscal first quarter.

Can Focus on High-Growth Area Up OrganiGram (OGI) Q1 Earnings?

OrganiGram (OGI) is expected to have benefited from its firm focus on building brand equity and ongoing product innovation in the fiscal first quarter.

Has Exact Sciences (EXAS) Outpaced Other Medical Stocks This Year?

Is (EXAS) Outperforming Other Medical Stocks This Year?

Can New Strategic Efforts Aid Apharia's (APHA) Q2 Earnings?

Apharia (APHA) is successfully running its global cannabis business with more than 1,200 team members globally.

Can Cannabis Therapy Drive Aphria's (APHA) Q2 Earnings?

Aphria (APHA) expects to deliver strong second-quarter fiscal 2020 results banking on solid performance of its cannabis therapy business.

Top Ranked Momentum Stocks to Buy for January 13th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, January 13th

Exact Sciences Rides on Cologuard, Eyes Merger Synergies

Exact Sciences (EXAS) continues to make a notable progress with its Cologuard business.

Walgreens Boots (WBA) to Post Q1 Earnings: What's in Store?

Higher comparable pharmacy sales and expanded comparable prescription volume are likely to have aided growth in Walgreens Boots' (WBA) Retail Pharmacy USA during the first quarter of fiscal 2020.

Has Exact Sciences (EXAS) Outpaced Other Medical Stocks This Year?

Is (EXAS) Outperforming Other Medical Stocks This Year?

Medtronic (MDT) to Report Q2 Earnings: What's in Store?

In the fiscal second quarter, Medtronic (MDT) is expected to have registered strong growth in its ICD and CRT product lines.

Exact Sciences (EXAS) Reports Q3 Loss, Tops Revenue Estimates

Exact Sciences (EXAS) delivered earnings and revenue surprises of 24.39% and 1.54%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Exact Sciences (EXAS) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Exact Sciences (EXAS) closed at $89.89, marking a +1.02% move from the previous day.